Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (1238)	11/13/2001 4:40:32 PM
From: tuck	Read Replies (1) \| Respond to of 1321

Michael, Excuse me? This is taken from the the subject post of this thread: >>The submission also included very encouraging data from a second study of PHOTOFRIN(R) in 17 patients with completely obstructing esophageal cancer who were considered to have no other acceptable treatment options. All patients who receive PHOTOFRIN(R) will be photosensitive until the drug has cleared from the body and are advised to protect themselves from exposure to direct sunlight or bright lights.<< snip edit: and from QLT's own site: qltinc.com I don't follow the company super closely, have they dropped this already? Cheers, Tuck